By Daniella Parra
Eterna Therapeutics Inc. (Nasdaq: ERNA) is partnering with Lineage Cell Therapeutics, Inc. to develop stem cell lines for central nervous system diseases, the company said.
Eterna’s mRNA gene-editing approach and Lineage’s expertise in gene editing aim to reduce immunogenicity, prevent immune responses and add a competitive advantage, it said.
“We are excited to move forward with the next phase of our partnership with Lineage,” Eterna CEO Matt Angel said. “We believe that pluripotent cell therapies have the potential to significantly outperform traditional approaches in certain settings, and this milestone highlights Eterna’s capabilities for generating novel gene-edited iPSC lines using our mRNA cell engineering platform.”